Pharmacy Benefits Management Services

United States Department of Veterans Affairs

PBM Home

Clinical Guidance

Abbreviated Reviews
Clinical Recommendations
Criteria for Use
Drug Class Reviews
Drug Monitoring
Drug Monographs
FAQ Sheets
Permission and Referencing PBM-MAP Documents
Pocket Cards
Therapeutic Interchange Guidance
VA National Clinical Practice Guidelines

Drug Prices, Contracts & Agreements

DoD Prices
Drug Pharmaceutical Prices
Prime Vendor Prices

Education

Distance Learning Broadcast and other Educational Opportunities
Mentor Certification Program
VA Pharmacy Residency Program
VA Learning Opportunities Residency (VALOR)

Links & Other Resources

National Formulary
Ez Minutes Newsletter
Formulary Principles Coalition (pdf)
Related Links

VA Center for Medication Safety - PSCI

About Us
Bulletins and News Alerts
Medication Safety In Seconds Newsletter
Drug Safety Features
Adverse Event Tracking Tools
Resources
Other VA Safety Projects
PGY2 Residency in Medication Safety and Outcomes Assessment
Prescription Safety

Clinical Guidance/Criteria For Use

Acamprosate, Criteria for Non-Formulary Use
Agalsidase, Criteria for Non-Formulary Use
Alemtuzumab, Criteria For Non-Formulary Use
Aliskiren, Criteria for Nonformulary Use
Alpha-Blocker and Finasteride Combination Therapy for BPH, Criteria for Use
Alpha-Blockers (Clinically Uroselective), Criteria for Nonformulary Use
Alvimopan, Criteria for Nonformulary Use
Aprepitant Criteria for Formulary Use
Azacitidine, Criteria for Formulary Use
Becaplermin (Regranex)-Criteria for NF Use
benzocaine
Bevacizumab, Criteria for Use
Biologics for Psoriasis, Criteria for Non-Formulary Use
Boceprevir, Criteria for Use
Buprenorphine, Criteria for Formulary Use
C1 Inhibitor (Berinert, Cinryze), Ecallantide for Hereditary Angioedema, Criteria for Use
Calcitriol Ointment Criteria for Use
Cholinesterase Inhibitors Criteria for Use Updated 7.31.08
Cilostazol, Non-Formulary Criteria For Use
Cinacalcet, Criteria for Use
Clopidogrel 01 2010
Collagenase Clostridium Histolyticum Criteria for Use
Cyclosporine Ophthalmic (Restasis) CFU
Dabigatran Criteria For Use
Dalfampridine (Ampyra) Criteria for Use
Deferasirox Criteria for Non-formulary Use
Denosumab (Prolia) Criteria For Use
Dexmedetomidine ICU Criteria for Formulary Use
Dexmedetomidine Peri-Operative Criteria for Formulary Use
DMARDs for Rheumatoid Arthritis (Leflunomide and Biologic Agents), Criteria for Use
DPP-4 Inhibitor Criteria for Use
Dronedarone, Criteria for Use
Drotrecogin Alfa Criteria for Non-Formulary Use
Duloxetine Criteria for Non-Formulary Use
Eculizumab Critiera for Nonformulary Use
Endothelin Receptor Antagonists (ERA), Criteria for Use (Oct 2008)
Enfuvirtide, Criteria for Formulary Use
Erlotinib, Criteria for Non-Formulary Use
Erythropoietin Criteria for Formulary Use for Hepatitis C, Criteria for Use
Eszopiclone, Criteria for Non-Formulary Use
Etravirine, Criteria for Use
Ezetimibe or Ezetimibe+Simvastatin Criteria for Nonformulary Use
Factor VII, Recombinant Activated (NovoSeven«), Criteria for Non-Formulary Use
Factor VII, Recombinant Activated (NovoSeven®), Criteria for Non-Formulary Use
Fentanyl Transdermal Patch Criteria for Use
Filgrastim for Hepatitis C Treatment-Related Neutropenia
Fingolimod (Gilenya) Criteria for Use
Fluoroquinolone, Criteria for Use
Fondaparinux Criteria For Use
Gefitinib Criteria for Non-Formulary Use
GLP-1 agonist (exenatide and liraglutide)
HPV Quadrivalent Vaccine, Criteria for Use
Hyaluronic Acid-Hylan G-F 20 Criteria for Use-(November 2009)
Imatinib, Criteria for Formulary Use
Imiquimod, Criteria for Formulary Use
Immune Globulin, Subcutaneous CFU
Interferon alfacon-1 (Consensus Interferon) in Hepatitis C
Levetiracetam, Criteria for Formulary Use
Lubiprostone, Criteria for Non-Formulary Use
Maraviroc, Criteria for Formulary Use
Memantine Criteria for Use Updated 7.31.08
Meperidine, Criteria for Use
Methylnaltrexone Injectable Nonformulary Criteria for Use
Monoamine Oxidase Inhibitors (MAOI), Criteria for Use
Montelukast Criteria for Use
Moxifloxacin Ophthalmic Solution, Criteria for Formulary Use
Naltrexone Inj Criteria for Nonformulary Use
Natalizumab CFU- update Jan 2010
Nicardipine IV Criteria for Use
Omalizumab, Criteria for Non-formulary Use
Omega-3-Acid Ethyl Esters (Lovaza«, formerly Omacor), Criteria For Non-Formulary Use
Omega-3-Acid Ethyl Esters (Lovaza®, formerly Omacor), Criteria For Non-Formulary Use
Orlistat - Criteria for Use
Oxycodone CR, Criteria for Use and Treatment Algorithm
Oxymorphone Oral Tablets, Criteria for Non-Formulary Use
Paliperidone palmitate IM Criteria for Use
Pantoprazole I.V. Criteria for Use and Literature Review
Parkinson's Disease (Initial Therapy Selection), Criteria for Use
Pegaptanib, Criteria for Non-Formulary Use
Pegfilgrastim, Criteria for Non-Formulary Use
Pemetrexed, Criteria for Non-Formulary Use
Phosphate Binder (Lanthanum, Sevelamer), Criteria for Use
Phosphate Binder (Lanthanum, Sevelamer), Criteria for Use
Pioglitazone Criteria for Use
Pramlintide Criteria for Use
Prasugrel Criteria for Non-Formulary Use
Pregabalin, Criteria for Nonformulary Use (Rev 2008 03 10)
Prostacyclins, Inhaled (Treprostinil and Iloprost), Criteria for Use
Proton Pump Inhibitors, High-dose, Criteria for Use
Ramipril, Criteria for Non-Formulary Use
Ranolazine, Criteria for Non-Formulary Use
Retinoids and High-dose Vitamin A (Highly Teratogenic), Criteria for Use
Rifaximin for Chronic Hepatic Encephalopathy Checkbox, Criteria for Use
Rifaximin for Chronic Hepatic Encephalopathy Document, Criteria for Use
Rilpivirine coformulated with TDF-FTC
Rilpivirine, Criteria for Use
Risperidone Long-acting IM Criteria for Use
Rituximab, Criteria for Use
Roflumilast Criteria for Use
Sinecatechins, Nonformulary Criteria for Use
Sitagliptin, Criteria for Non-formulary Use
Sorafenib in Hepatocellular Carcinoma, Criteria For Use
Statin Criteria for Use (Fluva-prava-atorva-rosuva)-(December 2011)
Statin, Criteria for Non-Formulary Use in Patients Receiving Protease Inhibitor Therapy
Tapentadol IR Tab Criteria for Use
Telaprevir, Critiera for Use
Teriparatide Criteria For Use
Tetrabenazine, Criteria for Use
Thickening Agents for Outpatients, Criteria for Use
Thrombopoietin Agonists, Criteria For Use
Tiotropium Criteria for Formulary Use
Tipranavir, Criteria for Formulary Use
Tocilizumab, Criteria For Use
Varenicline Criteria for Prescribing
Vitamin Supplements for Macular Degeneration, Criteria For Use
Ziconotide, Criteria for Non-Formulary Use
Ziprasidone IM, Criteria for Non-Formulary Use
Ziprasidone, Criteria for Use
Zoledronic Acid (Reclast) Criteria For Use
Zoster Vaccine

If you have a question pertaining to this website and only information contained in this website, please contact the PBM Webmaster. Please note: For questions pertaining to Health Care Benefits, please visit http://www.vba.va.gov/VBA/ . For questions pertaining to prescription renewal, please visit http://www.myhealth.va.gov/ . Questions pertaining to your drug therapy or other medical questions should be referred directly to your Health Care Providers located at the VA facilities where you receive care.